Board of directors


Gemma Voss, PhD

Chief Executive Officer

Gemma Voss has a MSc degree in Health Science and completed her PhD thesis ( “Severity of illness and cost of medical care in patients with Acute Myocardial infarction” ) at the Maastricht University in The Netherlands.

Gemma has more than 20 years of experience in implementing, supervising and supporting various Clinical Trials with a specialization in economic evaluation studies. Before joining Cardialysis, she was CEO of the Clinical Trial Center Maastricht BV (CTCM) for over 10 years. This company from the  Maastricht University Medical Center has been set up by her and has grown under her leadership into a leading Academic Research Organization in the Netherlands.


Irene Kuit, MA

Managing Director of Project Strategy

Irene Kuit joined Cardialysis in 2014 and has over 20 years of experience in clinical development in the CRO industry. In her current position, Irene is a member of the Executive Board of Cardialysis and develops business strategies and study delivery models for clinical studies. In her role, she is responsible for the direct operational oversight of Project Teams, as well as for the design, implementation, and maintenance of clinical operational processes.

Prior to joining Cardialysis, Irene assumed project management and key operational positions at Quintiles, PAREXEL, MIRAI/VERUM, Cardialysis and the Daniel Den Hoed cancer center. Her expertise lies in management principles and in the conduct of clinical trials in the field of cardiology (pharma and device). Irene has a MSc degree in Speech and Language Pathology at the University of Nijmegen, the Netherlands.


Ron van Amsterdam, PhD, DipPharMed

Managing Director Research and Business Development

Ron van Amsterdam joined Cardialysis in 2019 as a pharmacologist (PhD, Groningen-NL), medical scientist (Diplome of Pharmaceutical Medicine, Surrey-UK) and resource manager (Lean Six sigma Green Belt, Leiden NL) after over 25 years in pharma industry (at Organon, Pharming and Astellas in chronic inflammation, thrombosis, and anti-infectives).  In his current position, Ron is a member of the Executive Boards of Cardialysis and ECRI and develops business strategies around scientific and service opportunities that Cardialysis can provide in all cardiology areas, whether devices, diagnostics, pharmaceuticals, or novel patient treatment strategies.  He oversees scientific content and business opportunity creation from a perspective of Cardialysis’ corporate strengths.

Prior to joining Cardialysis, Ron assumed increasingly senior leadership roles in pharmacology, clinical pharmacology, medical science and clinical operations, published scientific papers, as well as inventions, and consulted in multiple drug registrations at CHMP and FDA.  His latest job since 2009, involved resource management for global drug development project management, program management in Nephrology and Urology, multiple improvement initiatives around Astellas’ R&D process and Organizational structure (closely working with US and Japanese peers), and facility management in The Netherlands until Astellas consolidated R&D activities outside Europe.